Plaque Psoriasis

Biologic therapy for psoriasis showed no significant impact on cardiovascular risk factors over one year in a retrospective study from Australia.

These results may support clinical decision-making for psoriasis and nail psoriasis management and may allow future real-world studies to further understand the nature of this skin disease.

A study showed tildrakizumab treated difficult-to-treat psoriasis areas in patients who failed anti-IL17 treatment.

The tool’s development for scoring severity among complex nail psoriasis cases and monitoring response to treatment may allow for improved outcomes among patients.

These data suggest that a multidisciplinary clinic approach results in several benefits including reduced risk of cardiovascular events among those with psoriasis.

These data highlight the elements known to impact patient-reported outcomes among those with psoriasis and successful clinician-reported outcomes following biologic use.

A new study found specific sociodemographic factors were linked to 76.4% lower odds of adhering to topical therapy for psoriasis.

In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.

This interview with Bunick featured a discussion of his team’s recent data comparing anti-IL-23 biologics, epitopes, and comparisons with risankizumab.

These data allow for a basis for additional research and possible interventions to address psoriasis patients’ demodicosis risk.

Experts conclude the series discussing how to approach switching psoriasis treatments.

Experts discuss package warnings associated with bimekizumab and how they inform patients of them.

Experts discuss bimekizumab for the treatment of psoriasis highlighting is efficacy over other treatments.

Dermatologists Drs Tina Bhutani and Scott Boswell and a patient share resources and tools available to cope with generalized pustular psoriasis (GPP).

Dermatologists Drs Tina Bhutani and Scott Boswell and a patient share resources and tools available to cope with generalized pustular psoriasis (GPP).

A patient and 2 dermatologists discuss the impact of generalized pustular psoriasis (GPP) on patient’s quality of life.

A new study found intensive topical therapy improves deep sleep and REM sleep for patients with psoriasis and atopic dermatitis after 2 weeks.

A recent meta-analysis of more than 60 studies suggests guselkumab and risankizumab had the longest drug survival of IL-17 and IL-23 inhibitors for psoriasis.

Experts emphasize the importance of collaboration with infectious disease specialists for patients with tuberculosis, while highlighting the low reactivation rates in newer agents.

Dermatologists Drs Tina Bhutani and Scott Boswell and a patient discuss unpredictable nature of generalized pustular psoriasis (GPP) and management of flares and GPP between flares.

Dermatologists Drs Tina Bhutani and Scott Boswell discuss use of spesolimab to treat generalized pustular psoriasis (GPP) flares.

In this analysis, investigators sought to assess PsA development probability in subclinical PsA as well as to characterize symptoms and patterns of subclinical PsA.

In this analysis, the study investigators highlighted the impact of smoking cigarettes on PASI 75 achievement.

Experts highlight how a history of cancer may impact psoriasis treatment decisions while touching on the safety profiles of newer IL agents.